EKSO BIONICS HOLDING (OTCBB:EKSO), a reputed robotic exoskeleton firm, confirmed that nine prominent centers in Europe including Institute Guttmann in Spain, The Clinic for Spinal Cord Injuries in Denmark, and SPZ Notwill in Switzerland are participating in a clinical trial to include almost 70 participants.
The trial will evaluate how Ekso GT may impact general outcomes and mitigate secondary problems. The complexities include pain, bowel and bladder dysfunction, commonly linked with spinal cord injury. The study is expected to be in the process for 30 months with early results expected next year.
The management view
Thomas Looby, the President and Chief Commercial Officer of Ekso said that the landmark trial is the first one of its type in the industry. While smaller, the previous studies have shown significant promise. It is the time for the company to take the charge of developing an effective dataset across a wide range of treatment protocols.
It will be a significant step ahead in translating a standard of care for ‘SCI rehabilitation’. The team of Ekso is delighted to be associated with these luminaries as they give way exoskeleton use with their patients.
The other details
The study coordinating center for Ekso study is the Clinic for Spinal Cord Injuries in Denmark at Glostrup and Rigshospitalet Hospital. The principal investigator appointed is Fin Biering-Sorensen, PhD. who heads the Department for Spinal Cord Injuries. The study will be supported by Professor Fin Biering-Soerensen who is past President of the ISCoS and a major contributor in SCI clinical research trials for many years.
Biering-Sorensen said that the physician and patient interest in the study have been encouraging, and the initial response to the research design has been positive. He added that he is delighted to lead the trial of this scope. The exoskeletons improve quality of life of patients with home use.